Top Markets
Coin of the day
GH Research PLC GH Research PLC

GH Research PLC

GHRS
株式のランク #6594
GH Research PLC is a clinical-stage biopharmaceutical firm dedicated to... GH Research PLC is a clinical-stage biopharmaceutical firm dedicated to creating novel therapies for psychiatric and neurological conditions. The company primarily concentrates on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) treatments, specifically targeting patients with treatment-resistant depression (TRD). Its most advanced program is GH001, an inhalable 5-MeO-DMT product candidate that has successfully completed two Phase 1 clinical trials and a subsequent Phase 1/2 clinical trial in TRD patients. Additionally, GH Research is developing GH002, an injectable 5-MeO-DMT candidate, and GH003, an intranasal 5-MeO-DMT candidate. Both GH002 and GH003 are currently in preclinical development, with a focus on their potential applications in various psychiatric and neurological disorders. Founded in 2018, GH Research PLC is headquartered in Dublin, Ireland.
株価
$28.53
時価総額
$1.96B
変化(1日)
-1.65%
変化(1年)
109.32%
IE
取引 GH Research PLC (GHRS)

カテゴリー

GH Research PLC(GHRS)の配当利回りの履歴
GH Research PLC(銘柄コード: GHRS)の配当利回り(TTM)は2026時点で0です。
過去5年間の平均配当利回り: 0.00%
GH Research PLC(GHRS)の2026から2026までの配当利回りの履歴
各年末時点の配当利回り(TTM)
配当利回り 変化
提供された日付のデータは十分ではありません。
類似企業または競合他社の配当利回り(TTM)